U
MACK

UBS’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

UBS’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$87K Buy
1,258
+356
+39% +$19K ﹤0.01% 6164
2014
Q2 		$52K Buy
902
+508
+129% +$25.8K ﹤0.01% 6820
2014
Q1 		$16K Sell
394
-381
-49% -$16.3K ﹤0.01% 8414
2013
Q4 		$33K Sell
775
-2,479
-76% -$71.9K ﹤0.01% 7533
2013
Q3 		$97K Buy
+3,254
New +$114K ﹤0.01% 6063

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

UBS's MACK Position: Q3 2014 in Review

UBS reduced its Merrimack Pharmaceuticals, Inc. (MACK) stake by 26% in Q3 2014, selling an estimated $382K and leaving 20,055 shares worth $1.39M. The position accounts for ﹤0.01% of the portfolio, ranked #3269.

UBS first reported a position in MACK in Q2 2013 and has held it in 6 quarters since. The position peaked at $1.56M in Q2 2014. 132 funds tracked by Wall St. Rank hold MACK as of Q3 2014.

  • UBS held 20,055 shares of Merrimack Pharmaceuticals, Inc. worth $1.39M as of Q3 2014.
  • UBS sold 7,140 Merrimack Pharmaceuticals, Inc. shares in Q3 2014, an estimated $382K.
  • Merrimack Pharmaceuticals, Inc. made up ﹤0.01% of UBS's portfolio in Q3 2014, its #3269 holding.
  • UBS first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and has held it in 6 quarters since.
  • UBS's Merrimack Pharmaceuticals, Inc. position peaked at $1.56M in Q2 2014.
  • 132 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.